化疗药物对Ⅱ期结直肠癌患者疗效的 Meta 分析

张 正鑫1, 杨 宏斌1, 仇 睿1, 杨 凯戈1, 许 倩2
1、承德医学院基础医学研究所
2、承德医学院基础医学研究所/河北省神经损伤与修复重点实验室

摘要


目的 系统评价化疗类药物对Ⅱ期结直肠癌患者是否获益。方法 使用计算机检索 PubMed、CNKI、Embase、Cochrane
和 WanFang Data 数据库，寻找涉及Ⅱ期结直肠癌患者的随机对照试验 (RCT)，比较应用化疗类药物与未应用化疗类药物的疗效
差异。本研究从建库之日起直至 2024 年 1 月 26 日期间进行文献检索。在对收集到的文献进行详细筛选后，研究者们仔细提取
并评估了所纳入研究中的偏倚风险。为了确保分析结果的准确性，采用 RevieW Manager 软件作为工具，对数据进行了严谨的
Meta 分析。结果 本研究共纳入了 4 项 RCTs。在这 4 个 RCTs 中，共有 1052 例患者参与。根据 Meta 分析的结果表明 ：Ⅱ期结
直肠癌化疗与无化疗患者的疗效 [RD=-0.27,95%CI(-0.53,-0.02),P<0.05] 比较，存在统计学差异。结论 以上结果显示，Ⅱ期
结直肠癌患者可以通过化疗获益。

关键词


化疗 ；结直肠癌 ；Meta 分析

全文:

PDF


参考


[1]Siegel RL,Miller KD,Wagle NS,et al. Cancer

statistics, 2023. CA Cancer J Clin. 2023,73(1):17-48.

[2]Yang Y,Wang HY,Chen YK,et al. Current status of

surgical treatment of rectal cancer in China[J]. Chin Med J

(Engl),2020,133(22):2703-2711.

[3]Kennecke HF,O'Callaghan CJ,Loree JM,et al.

Neoadjuvant Chemotherapy,Excision,and Observation

for Early Rectal Cancer:The Phase II NEO Trial

(CCTG CO.28) Primary End Point Results. J Clin

Oncol.2023,41(2):233-242.

[4]Slater S,Bryant A,Chen HC,et al. ctDNA guided

adjuvant chemotherapy versus standard of care adjuvant

chemotherapy after curative surgery in patients with

high risk stage II or stage III colorectal cancer: a multicentre,prospective, randomised control trial (TRACC Part

C). BMC Cancer.2023,23(1):257.

[5]Aranda E,Abad A,Carrato A,et al. Treatment

recommendations for metastatic colorectal cancer. Clin

Transl Oncol,2011,13(3):162-178.

[6]Heitzer E,Artl M,Filipits M,et al. Differential survival

trends of stage II colorectal cancer patients relate to promoter

methylation status of PCDH10,SPARC,and UCHL1. Mod

Pathol.2014,27(6):906-15.

[7]Wille-Jørgensen P,Syk I,Smedh K,et al. Effect of

More vs Less Frequent Follow-up Testing on Overall and

Colorectal Cancer-Specific Mortality in Patients With Stage

II or III Colorectal Cancer:The COLOFOL Randomized

Clinical Trial. JAMA.2018,319(20):2095-2103.

[8]Iveson T,Boyd KA,Kerr RS,et al. 3-month versus

6-month adjuvant chemotherapy for patients with highrisk stage II and III colorectal cancer: 3-year followup of the SCOT non-inferiority RCT. Health Technol

Assess.2019,23(64):1-88.

[9] 赵允杉 .680 例结直肠癌临床分析 [D]. 中国人民

解放军医学院 ,2013.

[10] Wu WKK,Law PTY,Lee CW,et al. MicroRNA

in colorectal cancer:from benchtop to bedside.

Carcinogenesis.2011,32: 247-253.

[11]Kim ST,Kim SY,Lee J,et al. Oxaliplatin (3months-

6months) With 6 Months of Fluoropyrimidine as Adjuvant

Therapy in Patients With Stage II/III Colon Cancer: KCSG

CO09-07. J Clin Oncol.2022,40(33):3868-3877.

[12]Morton D,Seymour M,Magill L,et al. FOxTROT

Collaborative Group. Preoperative Chemotherapy

for Operable Colon Cancer: Mature Results of an

International Randomized Controlled Trial. J Clin

Oncol.2023,41(8):1541-1552.

[13]Han Y,Lu S,Yu F,et al. A comparative analysis and

guidance for individualized chemotherapy of stage II and III

colorectal cancer patients based on pathological markers. Sci

Rep. 2016,6:37240.


Refbacks

  • 当前没有refback。